E4 Relief dose-finding study identifies 15 mg E4 as the optimal minimum dose for effective treatment of VMS (hot flushes) 15 mg E4 demonstrated a meaningful reduction of over 80% in VMS versus baseline, and a statistically significant reduction compared to placebo Safety profile consistent with previous E4 studies confirming Donesta®’s promising hemostatic and lipid […]
Liège, Belgium 16 April 2018 – 7:30 AM: Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, is pleased to announce the publication of its 2017 Annual Report and the invitation to its Ordinary General Shareholders’ meeting. Annual Report The Annual Report which outlines Mithra’s achievements in 2017 includes the following information: Overview of […]
https://www.mithra.com/wp-content/uploads/2018/04/ANNUAL-REPORT-IMG-EN.jpg13332000Mithra Pharmaceuticalshttps://www.mithra.com/wp-content/uploads/2017/05/logo-mithra-women-s-health.pngMithra Pharmaceuticals2018-04-16 07:30:122018-04-16 07:18:10Mithra releases 2017 Annual Report and invitation to its Ordinary General Shareholders’ Meeting
Mithra eligible for upfront milestones, recurring revenues and further sales-related payments, for a potential total deal value of at least EUR 50 million With Estelle®, Searchlight aims to further expand its growing footprint in Women’s Health Liège, Belgium, 12 April 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announced that it […]
https://www.mithra.com/wp-content/uploads/2016/07/cp-20-07-16.png9961500Mithra Pharmaceuticalshttps://www.mithra.com/wp-content/uploads/2017/05/logo-mithra-women-s-health.pngMithra Pharmaceuticals2018-04-12 07:30:022018-04-12 07:15:13Mithra Signs Principle Agreement for Commercialization of Estelle® in Canada with Women's Health Specialist Searchlight Pharma
Patent will strengthen and extend the existing Estelle® and E4 intellectual property estate Positive hemostasis data differentiate Estelle® from commonly prescribed combined oral contraceptives Liège, Belgium, 28 March 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has filed an additional patent application in Europe based on the […]
https://www.mithra.com/wp-content/uploads/2018/03/CP-27-03-18.png11302000Mithra Pharmaceuticalshttps://www.mithra.com/wp-content/uploads/2017/05/logo-mithra-women-s-health.pngMithra Pharmaceuticals2018-03-28 07:30:022018-03-28 07:44:28Mithra Applies for Additional Estelle® Patent Based on Positive Hemostasis Data
Estelle® Phase III studies remain on track to report top-line results in Q3 2018 from Europe/Russia and Q1 2019 from US/Canada Liège, 23 march 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that the minimum number of female cycles required by regulators in both of the pivotal Phase III Estelle® […]
Filing acceptance is a key regulatory milestone, confirming time line towards potential launch in the US by Mayne Pharma in H1 201 Pending FDA approval, Mithra is eligible for down payment and milestone payments totaling at least EUR 10 million Mithra to produce Myring™ for Mayne Pharma at its CDMO, with substantial annual revenues expected […]
https://www.mithra.com/wp-content/uploads/2017/01/press-release-12-01-17.jpg13201980Mithra Pharmaceuticalshttps://www.mithra.com/wp-content/uploads/2017/05/logo-mithra-women-s-health.pngMithra Pharmaceuticals2018-03-20 07:30:522018-03-20 07:18:39Mithra and Mayne Pharma’s Vaginal Contraceptive Ring Accepted for Filing by FDA
Mithra grants exclusive license for vaginal contraception ring to Alvogen for commercialization in Russia Agreement follows MyringTM licenses[1] closed with Mayne Pharma, Gynial and Adamed for the US, Austria and the Czech Republic, respectively Vaginal ring shall be manufactured at Mithra CDMO Liège, Belgium, 16 March 2018, 05:45 PM – Mithra (Euronext Brussels: MITRA), a […]
https://www.mithra.com/wp-content/uploads/2018/03/Russia.png8001280Mithra Pharmaceuticalshttps://www.mithra.com/wp-content/uploads/2017/05/logo-mithra-women-s-health.pngMithra Pharmaceuticals2018-03-16 17:45:412018-03-16 15:48:27Mithra and Alvogen Sign LSA for Vaginal Contraception Ring in Russia
Analysis across a range of parameters points to limited hemostatic impact for Estelle®, at least comparable to EE/LNG (Melleva®) and much lower than benchmark EE/DRSP (Yaz®) Results corroborate earlier findings and further delineate unique safety profile of Estelle® Liège, Belgium, March 08, 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today […]
Significant operational progress for highly promising E4 (Estetrol)-based pipeline, including 5th generation oral contraceptive Estelle® and next-generation menopause therapy Donesta® Important commercialization partnerships established with leaders in Women’s Health, including Libbs for Estelle® in Brazil, Fuji Pharma for Donesta® in Japan & ASEAN and Mayne Pharma for Myring™ in the US Strong revenue increase and […]
Results point to minimal changes in markers of coagulation and fibrinolysis, which is key to further delineate unique safety potential of Estelle® Detailed results available in coming weeks, with presentations at scientific conferences planned in Q1/Q2 Liège, Belgium, 08 February 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces that […]
Mithra Announces Positive Donesta® Phase IIb Study Achieving Primary Objective and Confirming Promising Safety Profile
/in Estetrol /by Mithra PharmaceuticalsE4 Relief dose-finding study identifies 15 mg E4 as the optimal minimum dose for effective treatment of VMS (hot flushes) 15 mg E4 demonstrated a meaningful reduction of over 80% in VMS versus baseline, and a statistically significant reduction compared to placebo Safety profile consistent with previous E4 studies confirming Donesta®’s promising hemostatic and lipid […]
Mithra releases 2017 Annual Report and invitation to its Ordinary General Shareholders’ Meeting
/in Corporate /by Mithra PharmaceuticalsLiège, Belgium 16 April 2018 – 7:30 AM: Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, is pleased to announce the publication of its 2017 Annual Report and the invitation to its Ordinary General Shareholders’ meeting. Annual Report The Annual Report which outlines Mithra’s achievements in 2017 includes the following information: Overview of […]
Mithra Signs Principle Agreement for Commercialization of Estelle® in Canada with Women’s Health Specialist Searchlight Pharma
/in Estetrol, News /by Mithra PharmaceuticalsMithra eligible for upfront milestones, recurring revenues and further sales-related payments, for a potential total deal value of at least EUR 50 million With Estelle®, Searchlight aims to further expand its growing footprint in Women’s Health Liège, Belgium, 12 April 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announced that it […]
Mithra Applies for Additional Estelle® Patent Based on Positive Hemostasis Data
/in Estetrol, News /by Mithra PharmaceuticalsPatent will strengthen and extend the existing Estelle® and E4 intellectual property estate Positive hemostasis data differentiate Estelle® from commonly prescribed combined oral contraceptives Liège, Belgium, 28 March 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that it has filed an additional patent application in Europe based on the […]
Mithra Announces Completion of Estelle® Cycles Required in Phase III Contraception Studies
/in Estetrol, News /by Mithra PharmaceuticalsEstelle® Phase III studies remain on track to report top-line results in Q3 2018 from Europe/Russia and Q1 2019 from US/Canada Liège, 23 march 2018 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that the minimum number of female cycles required by regulators in both of the pivotal Phase III Estelle® […]
Mithra and Mayne Pharma’s Vaginal Contraceptive Ring Accepted for Filing by FDA
/in Complex therapeutics, News /by Mithra PharmaceuticalsFiling acceptance is a key regulatory milestone, confirming time line towards potential launch in the US by Mayne Pharma in H1 201 Pending FDA approval, Mithra is eligible for down payment and milestone payments totaling at least EUR 10 million Mithra to produce Myring™ for Mayne Pharma at its CDMO, with substantial annual revenues expected […]
Mithra and Alvogen Sign LSA for Vaginal Contraception Ring in Russia
/in Complex therapeutics, News /by Mithra PharmaceuticalsMithra grants exclusive license for vaginal contraception ring to Alvogen for commercialization in Russia Agreement follows MyringTM licenses[1] closed with Mayne Pharma, Gynial and Adamed for the US, Austria and the Czech Republic, respectively Vaginal ring shall be manufactured at Mithra CDMO Liège, Belgium, 16 March 2018, 05:45 PM – Mithra (Euronext Brussels: MITRA), a […]
Mithra Presents Positive Hemostasis Results at ISGE Conference
/in Estetrol, News /by Mithra PharmaceuticalsAnalysis across a range of parameters points to limited hemostatic impact for Estelle®, at least comparable to EE/LNG (Melleva®) and much lower than benchmark EE/DRSP (Yaz®) Results corroborate earlier findings and further delineate unique safety profile of Estelle® Liège, Belgium, March 08, 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today […]
Mithra Reports 2017 Annual Results
/in Corporate, News /by Mithra PharmaceuticalsSignificant operational progress for highly promising E4 (Estetrol)-based pipeline, including 5th generation oral contraceptive Estelle® and next-generation menopause therapy Donesta® Important commercialization partnerships established with leaders in Women’s Health, including Libbs for Estelle® in Brazil, Fuji Pharma for Donesta® in Japan & ASEAN and Mayne Pharma for Myring™ in the US Strong revenue increase and […]
Mithra Announces Very Promising Hemostasis Results for Estelle®
/in Estetrol, News /by Mithra PharmaceuticalsResults point to minimal changes in markers of coagulation and fibrinolysis, which is key to further delineate unique safety potential of Estelle® Detailed results available in coming weeks, with presentations at scientific conferences planned in Q1/Q2 Liège, Belgium, 08 February 2018 – Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces that […]